ATE394474T1 - Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen - Google Patents
Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellenInfo
- Publication number
- ATE394474T1 ATE394474T1 AT98921011T AT98921011T ATE394474T1 AT E394474 T1 ATE394474 T1 AT E394474T1 AT 98921011 T AT98921011 T AT 98921011T AT 98921011 T AT98921011 T AT 98921011T AT E394474 T1 ATE394474 T1 AT E394474T1
- Authority
- AT
- Austria
- Prior art keywords
- antigen
- cells
- activated
- pbls
- loaded
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 210000000265 leukocyte Anatomy 0.000 abstract 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 210000003071 memory t lymphocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4594997P | 1997-05-08 | 1997-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE394474T1 true ATE394474T1 (de) | 2008-05-15 |
Family
ID=21940709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98921011T ATE394474T1 (de) | 1997-05-08 | 1998-05-07 | Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen |
| AT05076809T ATE491465T1 (de) | 1997-05-08 | 1998-05-07 | Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05076809T ATE491465T1 (de) | 1997-05-08 | 1998-05-07 | Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6600012B1 (de) |
| EP (3) | EP0986636B1 (de) |
| JP (1) | JP4480800B2 (de) |
| AT (2) | ATE394474T1 (de) |
| AU (1) | AU727863B2 (de) |
| CA (1) | CA2289742C (de) |
| DE (2) | DE69839443D1 (de) |
| DK (1) | DK1634949T3 (de) |
| ES (1) | ES2357960T3 (de) |
| WO (1) | WO1998050527A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19906744A1 (de) * | 1999-02-18 | 2000-08-24 | Martin Roecken | Verfahren zur Herstellung antitumoraler Th1-Zellen |
| EP1171612A2 (de) * | 1999-04-09 | 2002-01-16 | Biomira, Inc. | Telomerase-spezifisches krebsimpfstoff |
| DE19917195B4 (de) * | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
| JP2003510094A (ja) * | 1999-09-08 | 2003-03-18 | トランジェーヌ、ソシエテ、アノニム | Ｍｕｃ−１由来のペプチド |
| GB9921337D0 (en) * | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
| GB0007150D0 (en) * | 2000-03-24 | 2000-05-17 | Lamellar Therapeutics Limited | Immunotherapeutic methods and compositions |
| US8198400B2 (en) | 2001-03-27 | 2012-06-12 | Oncothyreon, Inc. | Vaccine for modulating between T1 and T2 immune responses |
| WO2003077864A2 (en) | 2002-03-15 | 2003-09-25 | Department Of Veterans Affairs, Rehabilitation R & D Service | Methods and compositions for directing cells to target organs |
| AU2003224878B2 (en) * | 2002-04-15 | 2009-07-09 | Oncothyreon Inc. | Synthetic glyco-lipo-peptides as vaccines |
| EP1537143A2 (de) * | 2002-09-05 | 2005-06-08 | Cell Center Cologne GmbH | Immunogene muc1-glykopeptide |
| KR20050062605A (ko) * | 2002-10-10 | 2005-06-23 | 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) | 종양 특이적 에피토프에 대해 지정된 표지된 활성화임파구를 이용한 종양의 검출, 위치결정 및 병기결정 |
| US20050045205A1 (en) * | 2003-08-29 | 2005-03-03 | Stach Steven R. | Apparatus and method for cleaning printed circuit boards |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| JP5060134B2 (ja) * | 2003-12-12 | 2012-10-31 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ |
| TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| WO2006050116A1 (en) * | 2004-11-02 | 2006-05-11 | Biomedical Research Models, Inc. | Methods of cancer treatment/prevention using cancer cell-specific surface antigens |
| ES2526344T3 (es) | 2005-06-28 | 2015-01-09 | Oncothyreon Inc. | Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1) |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| EP2025762A3 (de) | 2006-01-17 | 2009-09-30 | Health Research Inc. | Heteroduplex-Trackingassay |
| US20100059084A1 (en) * | 2008-09-10 | 2010-03-11 | Austin American Technology Corporation | Cleaning and testing ionic cleanliness of electronic assemblies |
| WO2011140595A2 (en) | 2010-05-10 | 2011-11-17 | 4G Vaccines Pty Ltd | Immunostimulatory and vaccine compositions |
| KR20140023903A (ko) | 2011-02-24 | 2014-02-27 | 온코타이레온, 인코포레이티드 | 항원보강제를 갖는 muc1 기초 당지질펩티드 백신 |
| JP6523685B2 (ja) | 2012-01-03 | 2019-06-05 | アメリカ合衆国 | Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ |
| CA2912269A1 (en) | 2013-05-14 | 2014-11-20 | Merck Patent Gmbh | Method of treating lung cancer by vaccination with muc-1 lipopeptide |
| WO2015058831A1 (en) | 2013-10-25 | 2015-04-30 | Merck Patent Gmbh | Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines |
| DK3558339T3 (da) | 2016-12-22 | 2024-02-26 | Cue Biopharma Inc | T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf |
| EP3565829A4 (de) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon |
| CN111010875B (zh) | 2017-03-15 | 2024-04-05 | 库尔生物制药有限公司 | 用于调节免疫应答的方法 |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| EP4149534A2 (de) | 2020-05-12 | 2023-03-22 | Cue Biopharma, Inc. | Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0765381B1 (de) | 1994-06-13 | 1999-08-11 | Unilever N.V. | Bleichaktivierung |
| AU710783B2 (en) * | 1994-06-14 | 1999-09-30 | Board Of Trustees Of The Leland Stanford Junior University | Methods for in vivo T cell activation by antigen-pulsed dendritic cells |
| AU5849796A (en) * | 1994-12-27 | 1996-08-07 | United Biomedical Inc. | Peptide ratchet libraries for ctl-inducing vaccines and therapeutics |
| US6168804B1 (en) * | 1995-06-07 | 2001-01-02 | University Of Alberta | Method for eliciting Th1-specific immune response |
| AU727308B2 (en) | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1998
- 1998-05-07 AT AT98921011T patent/ATE394474T1/de not_active IP Right Cessation
- 1998-05-07 CA CA2289742A patent/CA2289742C/en not_active Expired - Fee Related
- 1998-05-07 JP JP54847798A patent/JP4480800B2/ja not_active Expired - Fee Related
- 1998-05-07 EP EP98921011A patent/EP0986636B1/de not_active Expired - Lifetime
- 1998-05-07 EP EP10180388.0A patent/EP2341072A3/de not_active Withdrawn
- 1998-05-07 DE DE69839443T patent/DE69839443D1/de not_active Expired - Lifetime
- 1998-05-07 AT AT05076809T patent/ATE491465T1/de active
- 1998-05-07 DE DE69842060T patent/DE69842060D1/de not_active Expired - Lifetime
- 1998-05-07 ES ES05076809T patent/ES2357960T3/es not_active Expired - Lifetime
- 1998-05-07 EP EP05076809A patent/EP1634949B1/de not_active Expired - Lifetime
- 1998-05-07 DK DK05076809.2T patent/DK1634949T3/da active
- 1998-05-07 WO PCT/US1998/009288 patent/WO1998050527A1/en active IP Right Grant
- 1998-05-07 AU AU73712/98A patent/AU727863B2/en not_active Ceased
-
2000
- 2000-02-03 US US09/497,232 patent/US6600012B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU7371298A (en) | 1998-11-27 |
| DE69839443D1 (de) | 2008-06-19 |
| EP0986636A1 (de) | 2000-03-22 |
| EP0986636B1 (de) | 2008-05-07 |
| AU727863B2 (en) | 2001-01-04 |
| EP1634949B1 (de) | 2010-12-15 |
| CA2289742A1 (en) | 1998-11-12 |
| EP2341072A3 (de) | 2013-10-30 |
| WO1998050527A1 (en) | 1998-11-12 |
| JP2001525668A (ja) | 2001-12-11 |
| JP4480800B2 (ja) | 2010-06-16 |
| ES2357960T3 (es) | 2011-05-04 |
| US6600012B1 (en) | 2003-07-29 |
| CA2289742C (en) | 2013-07-16 |
| DK1634949T3 (da) | 2011-03-28 |
| EP2341072A2 (de) | 2011-07-06 |
| EP1634949A1 (de) | 2006-03-15 |
| ATE491465T1 (de) | 2011-01-15 |
| DE69842060D1 (de) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE394474T1 (de) | Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen | |
| ATE325802T1 (de) | Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben | |
| ATE330002T1 (de) | Verfahren zur herstellung von membranvesikeln | |
| ATE406906T1 (de) | Von survivin abstammende peptide und deren verwendung | |
| HK1208376A1 (en) | Artificial antigen presenting cell for preparing cd8 cell suspension for use in the treatment of cancer cd8 | |
| CY1109837T1 (el) | Διαγνωστικο και θεραπευτικο επιτοπιο | |
| ATE116329T1 (de) | Zellenfreier t-zellenantigenrezeptor und klinische verwendung. | |
| ES2177964T3 (es) | Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores. | |
| GR880100198A (el) | Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου. | |
| NZ514228A (en) | Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| EP1249490A3 (de) | In vitro Aktivierung von cytotoxischen T Zellen | |
| TR200001842T2 (tr) | Papilloma virüs kapsomer aşı formülasyonları- kullanım metotları. | |
| DE69734974D1 (de) | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen | |
| ES2132027A1 (es) | Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante. | |
| RU2000122041A (ru) | Способ лечения злокачественных опухолей головного мозга | |
| ATE276364T1 (de) | Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren | |
| UA36811A (uk) | Спосіб визначення антитоксичної здатності замінників шкіри |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |